Dear Colleagues,

Therapeutic targeting of RNA modulation has become a promising strategy for treating various types of disease, with emerging fields of noncoding-RNA-based therapeutics attracting the interest of biomedical research. Therapeutic targeting could provide beneficial advancements in comparison to existing therapies such as small molecule drugs or targeted antibodies. In this Special Issue, we invite papers on noncoding-RNA-based review/research papers interested in in vitro and in vivo models at preclinical and clinical levels. The Special Issue focuses explicitly on obstacles associated with specificity, delivery, and tolerability, and promises of targeting miRNA, long noncoding RNA, PIWI-interacting RNAs (piRNAs), circRNAs, and siRNA for different therapeutic modalities discussed in human diseases. We also invite papers to describe novel ex vivo methods based on human cells, tissues, virological diseases, and other infectious disease agents that could help to bridge the gap between in vivo models and biomedical applications. Additional factors, such as drug chemistry, drug formulations, different routes of administration, and the advantages of RNA-based drugs, are also invited to submit this Special Issue.

In summary, we are calling for manuscripts detailing the combination of novel therapeutic RNA targets, nanomaterials, nanovaccine formulations with a special interest in cancer, viral disease, and bacterial therapies, and novel delivery techniques. We sincerely hope that this Special Issue may serve as a valuable platform for exchanging the latest developments in noncoding-RNA-based clinical therapeutics, which will likely focus on promising emerging approaches that aim to boost their success toward next-generation therapy for human diseases.

Dr. Ramar Thangam
Dr. Ramasamy Paulmurugan
Dr. Heemin Kang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• RNA-based vaccines
• miRNA
• siRNA
• cancer therapy
• gene delivery
• virus-like particles
• nanopharmacology
• pharmaceuticals
• SARS-CoV-2
• COVID-19
• gene therapy
• immunotherapy
• preventive medicine